Archana Radhakrishnan, MD, MHS
Manage Your Profile
About
Dr. Archana Radhakrishnan is an Assistant Professor in the Department of Medicine at the University of Michigan. She is a primary care physician (PCP) practicing at the Ann Arbor VA and cancer health services researcher. She received her MD from the University of Illinois at Chicago and completed residency in Internal Medicine at Case Western Reserve University. She additionally completed a General Internal Medicine clinical research fellowship at Johns Hopkins University, where she also received a Master in Health Science (MHS) from the Bloomberg School of Public Health.
Dr. Radhakrishnan’s clinical and research interests align to ultimately improve the quality of care of patients with cancer. Specifically, she focuses on understanding and optimizing the role of PCPs in the care of patients throughout the cancer continuum. Her projects include examining the role of PCPs for patients with low-risk cancers. She is the PI on a NCI-funded K08 award to develop and test an intervention to engage PCPs to support men with low-risk prostate cancer on active surveillance. Currently, Dr. Radhakrishnan is developing and implementing team-based models involving PCPs to improve cancer survivorship care delivery.
Qualifications
-
General Internal Medicine Clinical Research FellowshipJohns Hopkins University School of Medicine, Baltimore, United States
2014 - 2017
-
MHSJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
2014 - 2016
-
MDUniversity of Illinois at Chicago College of Medicine, 1853 W. Polk (MC 785), Chicago, IL, 60612-7332, United States
2005 - 2009
Center Memberships
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
-
Center MemberInstitute for Healthcare Policy and Innovation
Recent Publications
-
Wallner LP, Furgal AKC, Veenstra CM, Kurian AW, Hamilton AS, Ward KC, Hawley ST, Katz SJ, Radhakrishnan A. J Cancer Surviv, 2026 May 11;Journal ArticlePatient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment.
DOI:10.1007/s11764-026-02038-w PMID: 42115496 -
Wallner LP, Furgal AKC, Veenstra CM, Kurian AW, Hamilton AS, Ward KC, Hawley ST, Katz SJ, Radhakrishnan A. J Cancer Surviv, 2026 May 11;Journal ArticlePatient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment.
DOI:10.1007/s11764-026-02038-w PMID: 42115496 -
Eary R, Erickson M, Ganschow PS, Gilmore KR, Hong S, Kim J, Manst D, McClellan S, McDonough AL, Peairs KS, Radhakrishnan A, Roth M, Siegel S, Schapira L, Topalian A, Yurkiewicz I, Nekhlyudov L, Choi Y. 2026 May 19;Proceeding / Abstract / PosterDeveloping quality cancer survivorship care competencies for primary care: a modified Delphi study
-
Eary R, Erickson M, Ganschow PS, Gilmore KR, Hong S, Kim J, Manst D, McClellan S, McDonough AL, Peairs KS, Radhakrishnan A, Roth M, Siegel S, Schapira L, Topalian A, Yurkiewicz I, Nekhlyudov L, Choi Y. 2026 May 19;Proceeding / Abstract / PosterDeveloping quality cancer survivorship care competencies for primary care: a modified Delphi study
-
Zaire P, Wallner LP, Radhakrishnan A. 2026 May 3;Proceeding / Abstract / PosterEvaluating Care Management as a System-Level Intervention for Colorectal Cancer Screening
-
Zaire P, Wallner LP, Radhakrishnan A. 2026 May 3;Proceeding / Abstract / PosterEvaluating Care Management as a System-Level Intervention for Colorectal Cancer Screening
-
Lewicki P, Jiang R, Radhakrishnan A, Bryant A, Schipper M, Morgan TM, Stensland K. Ann Intern Med, 2026 Mar; 179 (3): 321 - 329.Journal ArticlePredicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation.
DOI:10.7326/ANNALS-25-02036 PMID: 41525694 -
Lewicki P, Jiang R, Radhakrishnan A, Bryant A, Schipper M, Morgan TM, Stensland K. Ann Intern Med, 2026 Mar; 179 (3): 321 - 329.Journal ArticlePredicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test: Prognostic Model Development and External Validation.
DOI:10.7326/ANNALS-25-02036 PMID: 41525694